3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
106
Neoplasms
14
Neoplasm Metastasis
14
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Hereditary Sensory and Autonomic Neuropathies
3
Recurrence
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Endometrial Neoplasms
2
Breast Neoplasms, Male
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Malignancies
1
Recurrent Uterine Corpus Carcinoma
1
Neoplasms by Site
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Lethal Congenital Contracture Syndrome 2
1
Hyperglycemia
1
Hormone Receptor Positive HER-2 Negative Breast Cancer
1
Hormone Receptor Positive Breast Cancer
1
HER2-positive Breast Cancer
1
Female Breast Carcinoma
1
Exanthema
1
Interventions
Carboplatin
25
Bevacizumab
18
Paclitaxel
17
Pemetrexed
16
Erlotinib Hydrochloride
14
Radiotherapy
12
Docetaxel
9
Gemcitabine
7
Cisplatin
6
ceritinib
5
Taxes
5
Cetuximab
5
pembrolizumab
3
pegfilgrastim
3
capmatinib
3
Surgical Procedures, Operative
3
Radiosurgery
3
Metformin
3
Gefitinib
3
Cyclophosphamide
3
Thalidomide
2
Sorafenib
2
Radiotherapy, Conformal
2
Nivolumab
2
Immunoglobulin G
2
Filgrastim
2
Disulfides
2
Albumin-Bound Paclitaxel
2
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
2
veliparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Adenocarcinoma of Lung
×
Fulvestrant
×
Clear all
No trials found.